93866-50-3

Usage

Uses

Used in Organic Chemistry:
3-PHENYLETHYNYL-BENZOIC ACID is used as a building block for the synthesis of various aromatic compounds, contributing to the development of complex organic molecules and structures.
Used in Pharmaceutical Industry:
3-PHENYLETHYNYL-BENZOIC ACID is used as a precursor for the preparation of novel materials with potential applications in pharmaceuticals, owing to its anti-inflammatory and antioxidant properties, which can be harnessed for medicinal purposes.
Used in Materials Science:
3-PHENYLETHYNYL-BENZOIC ACID is utilized in the creation of new materials with unique properties, making it a valuable component in advancing the field of materials science.

InChI:InChI=1/C15H10O2/c16-15(17)14-8-4-7-13(11-14)10-9-12-5-2-1-3-6-12/h1-8,11H,(H,16,17)

Upstream product

• 135008-92-3 3-(2-(E)-phenylethenyl)-benzoic acid 
• 179244-72-5 ethyl 3-(2-phenylethynyl)benzoate 
• 207845-32-7 methyl 3-(2-phenylethynyl)benzoate 
• 536-74-3 phenylacetylene 
• 618-51-9 3-Iodobenzoic acid 

Downstream Products

• 123926-88-5 [3-(2-phenylethynyl)phenyl]methanol 
• 312521-94-1 1-[3-(phenylethynyl)benzoyl]-4-pyridin-2-ylpiperazine 

Relevant academic research and scientific papers

Development of Dipeptidic hGPR54 Agonists

A series of dipeptides were designed as potential agonists of the human KiSS1-derived peptide receptor (hGPR54). While the sequence Arg-Trp-NH2was the most efficient in terms of affinity, we established a convergent synthetic strategy to optimi

EBNA1 INHIBITORS AND THEIR METHOD OF USE

Pharmaceutical compositions of the invention comprise EBNA1 inhibitors useful for the treatment of diseases caused by EBNA1 activity such as cancer, infectious mononucleosis, chronic fatigue syndrome, multiple sclerosis, systemic lupus erythematosus and rheumatoid arthritis. Pharmaceutical compositions of the invention also comprise EBNA1 inhibitors useful for the treatment of diseases caused by latent Epstein-Barr Virus (EBV) infection. Pharmaceutical compositions of the invention also comprise EBNA1 inhibitors useful for the treatment of diseases caused by lytic Epstein-Barr Virus (EBV) infection.

Synthesis and characterization of a polymer-anchored palladium(II) Schiff base complex and its catalytic efficiency in phosphine-free Sonogashira coupling reactions

A polymer-anchored Pd(II) Schiff base complex has been synthesized by reacting a polymeric amine with 2-pyridinecarboxaldehyde to get the polymer-anchored Schiff base, which was then reacted with palladium acetate. The catalyst was characterized by physicochemical and spectroscopic methods. It shows excellent catalytic activity in the Sonogashira coupling of phenylacetylene with aryl halides using triethylamine as a base and copper iodide as a co-catalyst in water under open air at 70 °C. We have also studied the effects of base and solvent on the coupling reaction. Sonogashira reactions of phenylacetylene with a variety of functionalized aryl halides were performed under the optimized reaction conditions. This catalyst gives excellent yields without the use of phosphine ligands. Further experiments showed that the catalyst can be used five times without much loss in the catalytic activity. Springer Science+Business Media B.V. 2010.

PIPERAZINE METABOTROPIC GLUTAMATE RECEPTOR 5 (MGLUR5) NEGATIVE ALLOSTERIC MODULATORS FOR ANXIETY/DEPRESSION

The present teachings relate to piperazine metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulators having Formula (I); wherein the constituent variables are as defined herein. The present teachings further relate to methods for the preparation of the compounds, and to methods for using the compounds for treatment of diseases and disorders including schizophrenia, paranoia, depression, manic-depressive illness and anxiety.

Alpha-helical mimetics

Benzoyl urea derivatives that are alpha helical peptides mimetics that mimic BH3-only proteins, compositions containing them, their conjugation to cell-targeting-moieties, and their use in the regulation of cell death are disclosed. The benzoyl urea derivatives are capable of binding to and neutralizing pro-survival Bcl-2 proteins. Use of benzoyl urea derivatives in the treatment and/or prophylaxis of diseases or conditions associated with deregulation of cell death are also described.

ANTIBACTERIAL AGENTS

The present invention relates to antibacterial agents that are useful for sterilization, sanitation, antisepsis, and disinfection.